Leigh Syndrome is a usually lethal inherited orphan neurodegenerative and myodegenerative disease of infancy, caused by reductions in single mitochondrial proteins. IXC-109 dose-dependently increases gene expression of multiple mitochondrial proteins, and alleviates lethality and increases mitochondrial functions in the animal model of Leigh Syndrome.
Ixchel holds exclusive intellectual property rights to Compositions of Matter on multiple Novel MMF prodrugs, and Methods of Use.
© 2017 Ixchel Pharma
Friedreich's is the most common inherited recessive ataxia in the USA and Europe. Friedreich's is caused by the reduction of a single mitochondrial protein, frataxin, which leads to a lethal cardiomyopathy. Ixchel's IXC-109 dose-dependently increases frataxin protein, and uniquely rescues cardiac pathophysiology and lethality in animal models of Friedreich's. There is no approved therapy for Friedreich's in US or Europe, hence there is a large unmet need.